background: Recently, the American Diabetes Association (ADA) has included glycated hemoglobin A1 c (A1C) level as a component of diagnostic criteria of 'diabetes' or 'increased risk for diabetes'. This study was conducted to examine the prevalence of and risk factors for 'elevated A1C' (≥5.7%) in women with polycystic ovary syndrome (PCOS).
Introduction
Insulin resistance (IR) is a core pathophysiology of polycystic ovary syndrome (PCOS); thus, patients with PCOS carry an increased risk for development of type 2 diabetes (Ehrmann et al., 1999; Legro et al., 2005) . The screening recommendations for type 2 diabetes in patients with PCOS have varied according to organization: the Androgen Excess (AE) Society recommended that all patients with PCOS be screened for impaired glucose tolerance (IGT) with a 75-g oral glucose tolerance test (OGTT) (Salley et al., 2007) but recently the AE and PCOS Society recommended that an OGTT be performed in obese patients or in lean patients with advanced age (.40 year) and patients with a history of gestational diabetes or with a family history of type 2 diabetes (Wild et al., 2010) .
Traditionally, fasting or 75-g oral glucose have been used routinely in tests for the diagnosis of diabetes (Genuth et al., 2003) . Recently, the American Diabetes Association (ADA) has included the level of glycated hemoglobin A1 c (A1C) as a component of the diagnostic criteria for 'diabetes' (≥6.5% A1C) or 'increased risk for diabetes' (A1C 5.7 -6.4%) (American Diabetes Association, 2010) . In concert with ADA recommendations, the AE-PCOS Society also endorsed A1C criteria for assessment of diabetes in PCOS women. The purpose of this study was to examine the prevalence of and the risk factors for elevated A1C (≥5.7%) in women with PCOS compared with agematched controls.
Materials and Methods

Subjects
We recruited 154 patients with PCOS using the Rotterdam ESHRE/ ASRM-sponsored PCOS consensus workshop group (2004) . Clinical hyperandrogenism (HA) was defined as a modified Ferriman -Gallwey score (mF-G score) of 6 or greater , and biochemical HA was defined as follows: total testosterone .0.68 ng/ml, free testosterone .1.72 pg/ml and free androgen index (FAI) .5.36 (Chae et al., 2008) . To determine the proportion of patients with abnormal glycemic status for each PCOS phenotype, patients with PCOS were divided into four subgroups: (i) the IM (irregular menstruation)/HA/PCO (polycystic ovary group), (ii) the IM/HA group, (iii) the IM/PCO group or (iv) the HA/PCO group.
Patients with PCOS visited our clinic for various reasons but mainly because of IM, amenorrhea or prolonged vaginal bleeding (n ¼ 120), 13 patients were seeking infertility treatment and the remaining 21 women visited the clinic for routine cancer screening with no subjective complaints. None of the patients with PCOS who visited our clinic showed symptoms of clinical HA (hirsutism) only. The timings of blood sampling date for serum androgen tests were as follows: among 154 women with PCOS, 126 patients were sampled during the period of oligomenorrhea or amenorrhea, 22 patients were sampled during early follicular phase (Day 3 -5) of the menstrual cycle and in 3 patients, sampling was carried out during the period of prolonged vaginal bleeding. In the remaining three patients, the timing of sampling was not clear. All patients with PCOS were screened to exclude hyperprolactinemia and thyroid dysfunction. Serum 17-hydroxyprogesterone (17-OHP) was also measured and if serum 17-OHP level was .2 ng/ml, a repeat test was performed during the early morning follicular phase. Patients who showed continuous elevation of 17-OHP were excluded from the study group.
A total of 469 age-matched premenopausal women served as controls, and the match ratio was 1 -3. The criterion for matching was the same age, and BMI was not included in matching procedure. Control women visited Seoul National University Hospital as part of a group check-up for work and lacked specific health problems. All controls had regular (21-35 day) menstrual cycles, an mF-G score ,6 and all received a transvaginal or transrectal pelvic ultrasound examination to evaluate ovarian morphology and were excluded if PCO morphology was identified.
Information related to alcohol consumption and smoking was collected from self-completed, standardized history forms at the time of the check-up. None of the patients with PCOS and controls had taken combined oral contraceptives, lipid-lowering agents or insulin sensitizer or had a history of diagnosed diabetes. The institute review board (IRB) for human research of Seoul National University Hospital approved this project (IRB number: H-1005-050-319), and written informed consent was obtained from each woman.
Clinical and biochemical measurements
Clinical variables such as body weight, height, waist circumference and blood pressure were assessed in all subjects. Using radioimmunoassay (RIA) (Siemens, Los Angeles, CA, USA), serum levels of total testosterone, free testosterone and sex hormone-binding globulin (SHBG) were measured in all patients with PCOS and in a subset of controls (n ¼ 173) whose blood samples were taken during the follicular phase of the menstrual cycle. FAI was calculated as total testosterone/ SHBG × 100, and the values for testosterone were converted from ng/ ml to nmol/l using the following index proposed by the manufacturer: 1 ng/ml ¼ 3.467 nmol/l. The intra-and inter-assay coefficients of variation were 4.0 -11.0% and 5.9 -12.0% for total testosterone, and 4.0 -17% and 8.0 -18.3% for free testosterone, respectively.
In all subjects, after 12-h overnight fast, fasting plasma glucose (FPG) (hexokinase method), total cholesterol [cholesterol oxidase-N-(3-sulfopropyl)-3-methoxy-5-methylaniline (HMMPS) method], triglycerides (glycerol-3-phosphatase oxidase -HMMPS glycerol blanking), high-density lipoprotein (HDL)-cholesterol (selective elimination method) and low-density lipoprotein (LDL)-cholesterol (selective elimination method) were measured (Wako Pure Chemical Industries, Ltd. Osaka, Japan). Circulating highly sensitive C-reactive protein (hs-CRP) was measured using a latex turbidimetric immunoassay with a sensitivity of 0.01 mg/dl (Wako Pure Chemical Industries, Ltd). Fasting insulin levels were measured using RIA (BioSource Europe S.A., Belgium). The homeostatic model for IR was calculated by glucose (mg/dl) × insulin (mU/ml)/405, and homeostatic model assessment (HOMA bcell ) (%) was calculated as follows: (20 × fasting insulin)/(fasting glucose 23.5).
A1C was measured using an immunoturbidimetric assay with a COBAS Integra 800 system (Roche Diagnostics, Basel, Switzerland); intra-and inter-assay coefficients of variation were 0.8 -1.3%. The methodology was aligned with the Diabetes Control and Complications Trial and National Glycohemoglobin Standardization Program standards (http://www. ngsp.org/packets.asp).
Definition of elevated A1C
Although it has been recently suggested that A1C ≥5.6% predicts future diabetes in Koreans , we adopted 5.7% as the cut-off value for 'elevated A1C' for the convenience of further comparisons across ethnic groups (American Diabetes Association, 2010). Impaired fasting glucose (IFG) was defined by an elevated FPG concentration (≥100 and ,126 mg/dl) (Nathan et al., 2007) . Diabetes was diagnosed when FPG ≥126 mg/dl or A1C ≥6.5%.
Statistical analysis
Deviation of the data from a normal distribution was examined through visual inspection of quantile-normal plots and/or Shapiro-Wilk test of normality. Data are shown as mean + SD or median value with range. If Gaussian distribution was achieved by natural logarithmic or square root transformation, the data are shown as geometric means and 95% confidence intervals (95% CIs). Continuous parameters were compared using the Student's t-test or analysis of variance (ANOVA), and the prevalence of 'elevated A1C' was compared using the x 2 or Fisher's exact test. To assess the independent contribution of PCOS to elevated A1C, multivariate logistic regression analysis was conducted. All data analyses were performed using the Statistical Package for the Social Sciences software (version 17.0, SPSS Inc., Chicago, IL, USA), and significance was accepted for two-sided P , 0.05.
Results
Clinical and biochemical characteristics of the subjects are shown in Table I . The mean A1C levels in patients with PCOS and controls were 5.55 + 0.34% and 5.31 + 0.24%, respectively (P , 0.001).
One-third (31.2%) of the patients with PCOS had elevated A1C, and there was a significant difference in the prevalence of elevated A1C between the patients with PCOS and controls, and no difference in prevalence of IFG (Table II) . Only one woman with PCOS had both an A1C level ≥6.5% and FPG ≥126 mg/dl, and none of the controls had a diabetic range of A1C or FPG. All subjects were categorized by BMI (non-obese ,25 kg/m 2 and obese ≥25 kg/m 2 ) according to the definition of obesity for Asians (World Health Organization Western Pacific Region, 2000) , and the prevalence of elevated A1C and IFG analyzed (Table II) . The prevalence of elevated A1C was similar in obese women with PCOS and obese control women (23.5 and 20.0%, respectively, P ¼ 1.0) but non-obese women with PCOS (mean age 29.8 + 5.4 years) had a higher prevalence of elevated A1C than non-obese control women (31.0 versus 6.2%, respectively, P , 0.001).
To assess the independent contribution of PCOS to elevated A1C, multivariate logistic regression analysis was conducted. After adjusting for vascular disease risk factors, such as age, BMI, alcohol, smoking, hypertension, dyslipidemia and hs-CRP, the presence of PCOS was significantly associated with elevated A1C and the odds that a woman has an elevated A1C was 6.67 times higher if she has PCOS [adjusted odds ratio (OR) 6.67, 95% CI 3.50 -12.70, P , 0.001] (Table III) .
To determine the proportion of patients with abnormal glycemic status for each PCOS phenotype, patients with PCOS were divided into four subgroups according to the Rotterdam criteria, and their hormonal and metabolic features are presented in Supplementary data, 
Discussion
We have presented a case-control study of the prevalence of elevated A1C (≥5.7%) in Korean women with PCOS versus agematched controls. Non-obese patients with PCOS presented a higher prevalence of elevated A1C than non-obese controls. In addition, the mean age (29.8 + 5.3 years) of non-obese patients with PCOS was much lower than the recommended screening age: the AE-PCOS Society recommended that an OGTT be performed in obese patients or in lean patients of advanced age (.40 year) (Wild et al., 2010) . Taking our findings into consideration, screening for type 2 diabetes may be necessary even in young and non-obese patients with PCOS. As stated above, non-obese patients with PCOS presented a higher prevalence of elevated A1C than non-obese controls, whereas in obese subjects, the prevalence of elevated A1C was similarly elevated between patients and controls. These findings might suggest that IR, also reported in lean women with PCOS (Dunaif et al., 1989; Dunaif and Finegood, 1996) , results in higher prevalence of elevated A1C than non-obese controls, but obesity may blunt this distinction. However, considering the small number of obese subjects in our study, it is hard to draw conclusions on this obese population and further investigations are required.
In our data, the lack of difference in FPG underscores previous reports showing that women with PCOS commonly develop postprandial hyperglycemia prior to the development of IFG, which led to the recommendation to screen women with PCOS using the OGTT (Ehrmann et al., 1999; Legro et al., 1999; Palmert et al., 2002; Ehrmann et al., 2005; Wild et al., 2010) . Although we did not perform 75-g OGTTs in this study, we previously reported that the prevalence of IGT was 17.3 -20.0% in Korean patients with classic PCOS, with both oligo-or anovulation and HA (Chae et al., 2008) . It needs to be confirmed in future studies whether the prevalence of A1C abnormality may be higher than that of IGT among Korean women with PCOS. Recently, Hurd et al. (2011) compared various methods for diagnosing prediabetes and diabetes in women with PCOS and found that .10% of subjects with prediabetes according to OGTT were not detected by measuring A1C, but almost 20% additional subjects with normal OGTTs were identified by A1C as having prediabetes. The authors concluded that women with PCOS should be screened for prediabetes and diabetes using OGTT or A1C. The Hurd et al. (2011) study demonstrates the inconsistencies and limitations of current strategies for diabetes screening in patients with PCOS.
We detected a significant difference in mean A1C level between patients with PCOS and controls (5.55 + 0.34% versus 5.31 + 0.24%, respectively, P , 0. 001). The mean A1C level in patients with PCOS (mean age, 29.8 + 5.4 years old) was similar to those observed in older women (≥50 years), whereas mean A1C level in age-matched controls was similar to that of younger women (30 -39 years), as reported in a Korean population-based study (Sung and Rhee, 2007) . In addition, in the Sung and Rhee (2007) population study, an A1C level of 5.55% was the most appropriate cut-off (with the best balance between sensitivity and specificity, and area Only one woman with PCOS showed both an A1C level ≥6.5% and FPG ≥126 mg/dl. BMI for one diabetic woman with PCOS was missing. None of the control women had an A1C or FPG level in the diabetic range. *P , 0.001. **P ¼ 0.005; for age and BMI, the only significant finding was a difference in BMI between women with PCOS and controls, and non-obese women with PCOS and non-obese controls.
under the curve being .70.0%) for the presence of metabolic syndrome in Korean women. Considering these findings, a difference in mean A1C level between patients with PCOS and controls might have clinical significance in itself, and follow-up studies are needed to evaluate the relationship between A1C levels and cardiovascular events in women with PCOS.
There are some limitations in the present study. First, there were no OGTT data, and only a small number of obese subjects were enrolled. Second, although our findings were independent of several factors that affect glycemic status, including smoking and alcohol use, we cannot exclude the possibility of the presence of other potential confounding factors, such as differences in diet and/or exercise patterns. Third, only some of the controls (n ¼ 173) were evaluated for the presence of biochemical HA. A history of 'regular' menses does not exclude the presence of ovulatory dysfunction, and this 'subclinical ovulatory dysfunction' may be relatively common in some conditions, including HA (Azziz et al., 1998; Carmina, 1998) . However, this phenomenon is rare (0.7%) in normally menstruating women (Malcolm and Cumming, 2003) ; thus a lack of serum androgen measurements in controls is not likely to influence our results. Finally, A1C is known to increase with advancing age (RaviKumar et al., 2011) but in our data, women aged 30-39 years with PCOS showed decreased odds (adjusted OR 0.37, CI 0.19 -0.72) than other age groups. We are not sure what caused this association and the results should be interpreted with caution until replicated.
In summary, A1C may be a more appropriate screening tool than a fasting blood glucose level, especially in non-obese patients. As a substantial proportion of young and non-obese women with PCOS are at an increased risk for diabetes, screening for type 2 diabetes may be necessary even in these young, non-obese PCOS patients. In addition, future studies are essential to assess whether A1C is as effective as OGTT as a diagnostic tool for diabetes in Korean patients with PCOS. Daily alcohol consumption relies on the common exclusion of significant alcohol use ≥20 g/day (Brunt, 2001) . Hypertension was defined as a systolic blood pressure (BP) of ≥140 mmHg or a diastolic BP of ≥90 mmHg, or the use of hypertension medication. Dyslipidemia was defined according to the National Cholesterol Education Program criteria (total cholesterol ≥240 mg/dl, LDL-C ≥160 mg/dl, triglyceride ≥200 mg/dl, HDL-C ,40 mg/dl). CRP levels were categorized as ≤0.01 mg/dl or .0.01 mg/dl, according to the median (0.01 mg/dl) level.
Supplementary data
a Calculated with logistic regression models.
b Unadjusted odds ratio calculated by x 2 test was 6.398 (95% CI, 3.885 -10.538).
*P , 0.05.
